These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29725632)

  • 1. Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.
    Messchendorp AL; Meijer E; Boertien WE; Engels GE; Casteleijn NF; Spithoven EM; Losekoot M; Burgerhof JGM; Peters DJM; Gansevoort RT;
    Kidney Int Rep; 2018 Mar; 3(2):291-301. PubMed ID: 29725632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
    Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
    Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in tubular biomarkers with dietary intervention and metformin in patients with autosomal dominant polycystic kidney disease: a post-hoc analysis of two clinical trials.
    Wang W; You Z; Steele CN; Gitomer B; Chonchol M; Nowak KL
    BMC Nephrol; 2024 Jun; 25(1):206. PubMed ID: 38918734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease.
    Segarra-Medrano A; Martin M; Agraz I; Vilaprinyó M; Chamoun B; Jatem E; Molina M; Colàs-Campàs L; Garcia-Carrasco A; Roche S
    Clin Kidney J; 2020 Aug; 13(4):607-612. PubMed ID: 32905289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary biomarkers at early ADPKD disease stage.
    Petzold K; Poster D; Krauer F; Spanaus K; Andreisek G; Nguyen-Kim TD; Pavik I; Ho TA; Serra AL; Rotar L
    PLoS One; 2015; 10(4):e0123555. PubMed ID: 25875363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
    Phakdeekitcharoen B; Treesinchai W; Wibulpolprasert P; Boongird S; Klytrayong P
    BMC Nephrol; 2021 May; 22(1):178. PubMed ID: 33992075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
    Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
    BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations.
    Spithoven EM; Meijer E; Boertien WE; Sinkeler SJ; Tent H; de Jong PE; Navis G; Gansevoort RT
    Am J Kidney Dis; 2013 Sep; 62(3):531-40. PubMed ID: 23714171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.
    Dekker SEI; Verhoeven A; Soonawala D; Peters DJM; de Fijter JW; Mayboroda OA;
    PLoS One; 2020; 15(5):e0233213. PubMed ID: 32442208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary N-acetyl-β-D glucosaminidase as a surrogate marker for renal function in autosomal dominant polycystic kidney disease: 1 year prospective cohort study.
    Park HC; Hwang JH; Kang AY; Ro H; Kim MG; An JN; In Park J; Kim SH; Yang J; Oh YK; Oh KH; Noh JW; Cheong HI; Hwang YH; Ahn C
    BMC Nephrol; 2012 Aug; 13():93. PubMed ID: 22935351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of urinary epidermal growth factors with ADPKD disease severity and progression.
    Harskamp LR; Perez-Gomez MV; Heida JE; Engels GE; van Goor H; van den Heuvel MC; Streets AJ; Ong ACM; Ortiz A; Gansevoort RT;
    Nephrol Dial Transplant; 2023 Sep; 38(10):2266-2275. PubMed ID: 36914219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
    Griffin BR; You Z; Noureddine L; Gitomer B; Perrenoud L; Wang W; Chonchol M; Jalal D;
    Am J Nephrol; 2020; 51(6):473-479. PubMed ID: 32541154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate.
    Damman K; Van Veldhuisen DJ; Navis G; Vaidya VS; Smilde TD; Westenbrink BD; Bonventre JV; Voors AA; Hillege HL
    Heart; 2010 Aug; 96(16):1297-302. PubMed ID: 20659949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients.
    Dekker SEI; Verhoeven A; Frey D; Soonawala D; Peters DJM; Mayboroda OA; de Fijter JW;
    Am J Nephrol; 2022; 53(6):470-480. PubMed ID: 35613556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease.
    Chapman AB; Bost JE; Torres VE; Guay-Woodford L; Bae KT; Landsittel D; Li J; King BF; Martin D; Wetzel LH; Lockhart ME; Harris PC; Moxey-Mims M; Flessner M; Bennett WM; Grantham JJ
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):479-86. PubMed ID: 22344503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L; Radosevic A; Quintian C; Montañés R; Gràcia S; Vilaplana C; Mojal S; Ballarin JA; Fernández-Llama P; Torra R; Pascual J
    PLoS One; 2017; 12(3):e0174583. PubMed ID: 28346513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial.
    Miller ER; Juraschek SP; Anderson CA; Guallar E; Henoch-Ryugo K; Charleston J; Turban S; Bennett MR; Appel LJ
    Diabetes Care; 2013 Jun; 36(6):1462-9. PubMed ID: 23275364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure.
    Jungbauer CG; Uecer E; Stadler S; Birner C; Buchner S; Maier LS; Luchner A
    Nephrology (Carlton); 2016 Jun; 21(6):490-8. PubMed ID: 26422793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
    Shinke H; Masuda S; Togashi Y; Ikemi Y; Ozawa A; Sato T; Kim YH; Mishima M; Ichimura T; Bonventre JV; Matsubara K
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):989-96. PubMed ID: 26407820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.